Chengda Pharmaceutical said on the interactive platform that the company uses synthetic biotechnology such as enzyme catalysis to improve the quality of related products and reduce production costs. In the first quarter of 2024, Shanghai Chengjiutai Biomedical Co., Ltd., a wholly-owned subsidiary of the company, signed a technology implementation license, transfer, and cooperative development contract with Chiron Pharma, Inc. of the United States. The two parties reached technical sharing cooperation on stem cell treatment for heart failure indications after myocardial infarction (hereinafter referred to as the “myocardial infarction project”) and the treatment of subacute sequelae after a stroke (hereinafter referred to as the “cerebral infarction project”). The above 2 projects have obtained clinical approval from the US FDA. Chengjiutai purchased plant No. 15 of the Lingang Intelligent Manufacturing Park Phase 11 project in Fengxian District of Shanghai. The plant has a construction area of 5,910.6 square meters, which will later be used to carry out stem cell projects.